Advaxis Incorporated, a development stage biotechnology company, is poised for a major advancement if their Phase II cervical cancer vaccine data reflects the same optimistic survival data from prior Phase I data. New York, NY (PRWEB) May 02, 2011 Advaxis Incorporated, a development stage biotechnology company, is poised for a major advancement if their Phase II cervical cancer vaccine data reflects the same optimistic survival data from prior Phase I data.

Tom Moore, CEO of Advaxis, Inc. (OTCBB: ADXS, http://www.advaxis.com), will present at the 7th Annual BIO Investor Forum. The conference is being held at the Palace Hotel in San Francisco, October 29-31, 2008.

Advaxis Incorporated (OTCBB: ADXS) has provided a complete response to the FDAs questions regarding the proposed use in humans of Lovaxin C, a live Listeria vaccine directed against HPV induced disease, in the treatment of CIN.

Advaxis Incorporated (OTCBB: ADXS), a developmental biotechnology company, and a team of investigators from the University of Pennsylvania and the Hilman Cancer Center in Pittsburgh recently published a research paper in the October 2008 edition of Cancer Research demonstrating the tumor eliminating properties of a live Listeria monocytogenes (Lm) vaccine in a variety of different of cancer types in a mouse model.

Advaxis Incorporated (OTCBB: ADXS) Chairman and CEO Tom Moore will present at this year's World Vaccine Congress 2008, being hosted at Le Palais des Congres de Lyon in Lyon, France. The Conference will be held October 6 - 9, 2008. Mr.